Ocera Therapeutics

company

About

Ocera Therapeutics is a biopharmaceutical company developing novel therapeutics for patients with acute and chronic liver diseases.

  • Palo Alto,California,United States
  • 11 - 50

Details

Last Funding Type
Series C
Last Funding Money Raised
$35.50M
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jan 1, 2005
Number Of Employee
11 - 50
Operating Status
Active
Stock Symbol
nasdaq:OCRX
Legal Name
Ocera Therapeutics, Inc.
Also Known As
TRANZYME INC.,Renovia Inc

Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.

Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$151M
Ocera Therapeutics has raised a total of $151M in funding over 2 rounds. Their latest funding was raised on Aug 3, 2015 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 3, 2015 Post-IPO Debt $20M 3 Detail
Nov 6, 2013 Post-IPO Equity $28M 8 Detail
Mar 30, 2012 Post-IPO Debt $1.50M Detail
Apr 4, 2011 IPO $54M Detail
Feb 20, 2008 Series C $35.50M 9 Greenspring Associates Detail

Employee Profiles

Number of Employee Profiles
13
Ocera Therapeutics has 13 current employee profiles, including Board member Pratik Shah
Board member
Board member
Board member
Executive
Board member